For example, the widely used FDA-approved cobas® EGFR Mutation Test only detects exon 19 deletion and L858R mutations, which together only comprise the mutations found in 85% of EGFR-mutated lung cancers [12]. This evidence concerns the gene EGFR and lung carcinoma.